Superworth

Savara revenue SVRA

Sales by quarter and over the last twelve months, from 2013.

Last 12 months, to Jun 30, 2024
n/m
a quarter missing
Latest quarter, Q2 FY24
$0
Fiscal year 2020
n/a

Savara's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY24, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2020n/an/a
FY2016$128Kn/a
FY2015$0n/a
FY2014$0n/a
FY2013n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY24$0n/an/a
Q1 FY24$0n/an/a
Q3 FY23$0n/an/a
Q2 FY23$0n/an/a
Q1 FY23$0n/an/a
Q3 FY22$0n/an/a
Q2 FY22$0n/an/a
Q1 FY22$0n/an/a
Q3 FY21$0−100%n/a
Q4 FY20$1Kn/an/a
Q3 FY20$256Kn/an/a
Q1 FY17$94Kn/a$222K

Against its peers

Companies in Drug Manufacturers - General nearest Savara's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
SVRASavaran/m
ABUSArbutus Biopharma$181.7M
COLLCollegium Pharmaceutical$808.2M+14% a year
AMPHAmphastar Pharmaceuticals$730M+1% a year
OMEROmerosn/m
CRMDCorMedix$462.2M+281% a year
ZVRAZevra Therapeutics$136.1M+119% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
PBYIPuma Biotechnology$231.2M−3% a year
PCRXPacira BioSciences$746.2M+6% a year
ANABAnaptysbion/m
Peer median$425.8M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Savara

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.